|PDB structures||RCSB PDB PDBe PDBsum|
|Gene Ontology||AmiGO / EGO|
Thioredoxin reductases (TR, TrxR) (EC 188.8.131.52) are the only known enzymes to reduce thioredoxin (Trx). Two classes of thioredoxin reductase have been identified: one class in bacteria and some eukaryotes and one in animals. Both classes are flavoproteins which function as homodimers. Each monomer contains a FAD prosthetic group, a NADPH binding domain, and an active site containing a redox-active disulfide bond.
Thioredoxin reductase is the only enzyme known to catalyze the reduction of thioredoxin and hence is a central component in the thioredoxin system. Together with thioredoxin (Trx) and NADPH this system's most general description is as a method of forming reduced disulfide bonds in cells. Electrons are taken from NADPH via TrxR and are transferred to the active site of Trx, which goes on to reduce protein disulfides or other substrates. The Trx system exists in all living cells and has an evolutionary history tied to DNA as a genetic material, defense against oxidative damage due to oxygen metabolism, and redox signaling using molecules like hydrogen peroxide and nitric oxide.
Two classes of thioredoxin reductase have evolved independently:
- A high molecular weight (MW = ~55,000) type containing a selenocysteine residue in its active site has been identified in higher eukaryotes including humans. This TxR is related to glutathione reductase, trypanothione reductase, mercuric reductase and lipoamide dehydrogenase.
- A low molecular weight (MW = ~ 35,000) type has been identified in archaea, bacteria and other eukarya.
These two classes of TrxR have only ~20% sequence identity in the section of primary sequence where they can be reliably aligned. The net reaction of both classes of TrxR is identical but the mechanism of action of each is distinct.
Humans express three thioredoxin reductase isozymes: TrxR1 (cytosolic), TrxR2 (mitochondrial), TrxR3 (testis specific). Each isozyme is encoded by a separate gene:
E. coli thioredoxin reductase structure: In E. coli ThxR there are two binding domains, one for FAD and another for NADPH. The connection between these two domains is a two-stranded anti-parallel f3-sheet. Each domain individually is very similar to the analogous domains in glutathione reductase, and lipoamide dehydrogenase but they relative orientation of these domains in ThxR is rotated by 66 degrees. This becomes significant in the enzyme mechanism of action which is described below. ThxR homo-dimerizes with the interface between the two monomers formed by three alpha-helicies and two loops. Each monomer can separately bind a molecule of thioredoxin.
Mammalian thioredoxin reductase structure: Mammalian TrxR structure is similar to E. coli. It contains a FAD and NADPH binding domain, and an interface between two monomer subunits. In mammalian ThxR there is an insertion in the FAD binding domain between two alpha helices which forms a small pair of beta strands. The active disulfide in the enzyme is located on one of these helices and thus the active disulfide bond is located in the FAD domain and not the NADPH domain as in E. coli and other prokaryotes.
E. coli thioredoxin reductase mechanism: In E. coli ThxR the spatial orientation of the FAD and NADPH domains are such that the redox-active rings of FAD and NADPH are not in close proximity to each other. When the FAD domain of E. coli is rotated 66 degrees with the NADPH domain remaining fixed the two prosthetic groups move into close contact allowing electrons to pass from NADPH to FAD and then to the active site disulfide bond. The conserved active site residues in E. coli are -Cys-Ala-Thr-Cys-.
Mammalian thioredoxin reductase mechanism: Mammalian TrxRs have a much higher sequence homology with glutathione reductase than E. coli. The active-site Cys residues in the FAD domain and bound NADPH domain are in close proximity removing the necessity for a 66 degree rotation for electron transfer found in E. coli. An additional feature of the mammalian mechanism is the presence of a selenocystine residue at the C-terminal end of the protein which is required for catalytic activity. The conserved residues in mammalian active site are -Cys-Val-Asn-Val-Gly-Cys-.
- In cancer treatment: Since the activity of this enzyme is essential for cell growth and survival, it is a good target for anti-tumor therapy. Furthermore, the enzyme is upregulated in several types of cancer, including malignant mesothelioma. For example, motexafin gadolinium (MGd) is a new chemotherapeutic agent that selectively targets tumor cells, leading to cell death and apoptosis via inhibition of thioredoxin reductase and ribonucleotide reductase.
- In cardiomyopathy: Dilated cardiomyopathy (DCM) is a common diagnosis in cases of congestive heart failure. Thioredoxin reductases are essential proteins for regulating cellular redox balance and mitigating the damage caused by reactive oxygen species generated via oxidative phosphorylation in the mitochondria. Inactivation of mitochondrial TrxR2 in mice results in thinning of the ventricular heart walls and neonatal death. Furthermore two mutations in the TrxR2 gene are found in patients diagnosed with DCM and not in a control population. It is hypothesized that the pathological impact of these mutations is an impaired ability to control oxidative damage in cardiac myocytes.
- Mustacich D, Powis G (February 2000). "Thioredoxin reductase". Biochem. J. 346 (Pt 1): 1–8. doi:10.1042/0264-6021:3460001. PMC 1220815. PMID 10657232.
- Hirt RP, Müller S, Embley TM, Coombs GH (July 2002). "The diversity and evolution of thioredoxin reductase: new perspectives". Trends Parasitol. 18 (7): 302–8. doi:10.1016/S1471-4922(02)02293-6. PMID 12379950.
- Holmgren, A., Jun Lu (2010). "Thioredoxin and thioredoxin reductase: Current research with special reference to human disease". Biochemical and Biophysical Research Communications 396 (1): 120–4. doi:10.1016/j.bbrc.2010.03.083. PMID 20494123.
- Meyer, Yves; Bob B. Buchanan, Florence Vignols, and Jean-Philippe Reichheld (2009). "Thioredoxins and glutaredoxins: unifying elements in redox biology". Annual Reviews Genetics 43: 335–367. doi:10.1146/annurev-genet-102108-134201. PMID 19691428.
- Lillig, Christopher; Arne Holmgren (January 2007). "Thioredoxin and Related Molecules–From Biology to Health and Disease". Antioxidants & Redox Signaling 9 (1): 25–47. doi:10.1089/ars.2007.9.25. PMID 17115886.
- Arscott LD, Gromer S, Schirmer RH, Becker K, Williams CH (April 1997). "The mechanism of thioredoxin reductase from human placenta is similar to the mechanisms of lipoamide dehydrogenase and glutathione reductase and is distinct from the mechanism of thioredoxin reductase from Escherichia coli". Proc. Natl. Acad. Sci. U.S.A. 94 (8): 3621–6. doi:10.1073/pnas.94.8.3621. PMC 20490. PMID 9108027.
- Conrad M, Jakupoglu C, Moreno SG, Lippl S, Banjac A, Schneider M, Beck H, Hatzopoulos AK, Just U, Sinowatz F, Schmahl W, Chien KR, Wurst W, Bornkamm GW, Brielmeier M. (2004). "Essential role for mitochondrial thioredoxin reductase in hematopoiesis, heart development, and heart function". Mol. Cell. Biol. 24 (21): 9414–23. doi:10.1128/MCB.24.21.9414-9423.2004. PMC 522221. PMID 15485910.
- Williams Jr., Charles (1995). "Mechanism and structure of thioredoxin reductase from Escherichia coli". FASEB J. 9 (13): 1267–76. PMID 7557016.
- Sandalova, Tatyana; Liangwei Zhong; Ylva Lindqvist; Arne Holmgren; Gunter Schneider (August 2001). "Three-dimensional structure of a mammalian thioredoxin reductase: Implications for mechanism and evolution of a selenocysteine-dependent enzyme". PNAS 98 (12): 9533–8. doi:10.1073/pnas.171178698. PMC 55487. PMID 11481439.
- Lennon, Brett; Charles H. Williams, Jr. (1997). "Reductive Half-Reaction of Thioredoxin Reductase from Escherichia coli". Biochemistry 36 (31): 9464–77. doi:10.1021/bi970307j. PMID 9235991.
- Zhong, Liangwei; Elias S. J. Arner; Arne Holmgren (May 2000). "Structure and mechanism of mammalian thioredoxin reductase: The active site is a redox-active selenolthiolyselenenylsulfide formed from the conserved cysteine-selenocysteine sequence". PNAS 97 (11): 5854–5859. doi:10.1073/pnas.100114897. PMC 18523. PMID 10801974.
- Becker, Katja; Christel Herold-Mende, Jenny J. Park,§ Gordon Lowe, and R. Heiner Schirmer (2001). "Human Thioredoxin Reductase Is Efficiently Inhibited by (2,2':6',2-Terpyridine)platinum(II) Complexes. Possible Implications for a Novel Antitumor Strategy". Journal of Medicinal Chemistry 44 (17): 2784–92. doi:10.1021/jm001014i. PMID 11495589.
- Nilsonne G, Sun X, Nyström C, Rundlöf AK, Potamitou Fernandes A, Björnstedt M, Dobra K (September 2006). "Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress". Free Radic. Biol. Med. 41 (6): 874–885. doi:10.1016/j.freeradbiomed.2006.04.031. PMID 16934670.
- Kahlos K, Soini Y, Säily M, Koistinen P, Kakko S, Pääkkö P, Holmgren A, Kinnula VL (May 2001). "Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma". Int. J. Cancer 95 (3): 198–204. doi:10.1002/1097-0215(20010520)95:3<198::AID-IJC1034>3.0.CO;2-F. PMID 11307155.
- Hashemy SI, Ungerstedt JS, Zahedi Avval F, Holmgren A (April 2006). "Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase". J. Biol. Chem. 281 (16): 10691–10697. doi:10.1074/jbc.M511373200. PMID 16481328.
- Sibbing D, Pfeufer A, Perisic T, Mannnes, A.M., Fritz-Wolf, K., Unwin, S., Sinner, M.F., Geiger, C., Gloeckner, C.J., Wichmann, H.E., Kremmer, E., Schafer, Z., Walch, A., Hinterseer, M., Nabauer, M., Kaab, S., Kastrati, A., Schomig, A., Meitinger, T., Bornkamm, G.W., Condrad, M., Beckerath, N. (January 2011). "Mutations in the mitochondrial thioredoxin reductase gene TXNRD2 cause dilated cardiomyopathy". Eur. Heart J. 32 (9): 1121–1133. doi:10.1093/eurheartj/ehq507. PMID 21247928.
- Thioredoxin Reductase (NADPH) at the US National Library of Medicine Medical Subject Headings (MeSH)